What is HC Wainwright’s Forecast for Precigen Q1 Earnings?

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright decreased their Q1 2025 earnings estimates for Precigen in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.04). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.06) EPS.

Separately, JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Precigen Trading Down 6.0 %

Shares of PGEN opened at $1.71 on Monday. The stock has a market cap of $502.81 million, a P/E ratio of -3.11 and a beta of 1.58. The stock’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $1.17. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.30 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%.

Institutional Investors Weigh In On Precigen

Several large investors have recently modified their holdings of the business. Envestnet Asset Management Inc. grew its position in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 5,915 shares during the period. Invesco Ltd. boosted its holdings in shares of Precigen by 14.6% in the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 6,040 shares during the period. ProShare Advisors LLC increased its position in shares of Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 10,900 shares in the last quarter. Stoneridge Investment Partners LLC raised its holdings in shares of Precigen by 21.3% during the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 12,063 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Precigen by 12.0% in the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 12,285 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.